People
Scott Myers Named as Chairman of the Board at BioClin Therapeutics
6 July 2018 - - San Leandro, California-based clinical stage biotechnology company BioClin Therapeutics, Inc. has appointed Scott D. Myers as chairman of board of directors, the company said.
Myers was most recently chief executive officer (CEO), president, and a director of oncology company Cascadian Therapeutics, until it was acquired in March of 2018.
Prior to Cascadian, Myers was CEO of Aerocrine AB until 2015 when it was acquired. He has also held previous positions in senior commercial operation, general management and information management positions for UCB SA, a Belgium based biopharmaceutical company, and Johnson and Johnson.
Privately-held BioClin is developing biologics to address medical conditions in areas of high unmet need. The company is focused on fibroblast growth factor receptor 3, a driver mutation in metastatic bladder cancer and potentially other cancers.
BioClin has ongoing clinical studies in metastatic bladder cancer using multiple therapeutic approaches with the company's lead program B-701 as monotherapy, in combination therapies with standard-of-care chemotherapy, as well as with pembrolizumab, an immune checkpoint inhibitor.
Login
Username:

Password: